You are here

Home

THERATARGET, INC.

Company Information
Address
2500 S STATE ST STE D224
SALT LAKE CITY, UT 84115-3164
United States


http://www.theratarget.com
Information

UEI: KGMNGV6P8533

# of Employees: 5
Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts




Award Listing

  • Record 1 TO 6

  1. Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms

    Amount: $400,000.00

    NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk e ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health

  2. In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    Amount: $1,495,828.00

    SUMMARY This STTR Phase II proposal addresses the significant need for improved treatment options for patients with liver cancerthe fifth highest incidence of cancer in the worldBecause of the lack of ...

    STTRPhase II2016Department of Health and Human Services National Institutes of Health

  3. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    Amount: $995,235.00

    DESCRIPTION provided by applicant The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents gemcitabine and paclitaxel B ...

    STTRPhase II2014Department of Health and Human Services National Institutes of Health

  4. In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): This Phase I proposal addresses the significant need for improved treatment options for patients with liver cancer, the fifth highest incidence of cance in the wo ...

    STTRPhase I2012Department of Health and Human Services National Institutes of Health

  5. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    Amount: $148,304.00

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of targeted, backbone degradable, long-circulating polymer ...

    STTRPhase I2011Department of Health and Human Services National Institutes of Health

  6. Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of a polymeric delivery system that will deliver two antic ...

    STTRPhase I2010Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government